Unfractionated Heparin Market

Unfractionated Heparin (UFH) is a fast-acting blood thinner that works together with antithrombin, a natural protein in the body, to block clot formation. Specifically, UFH binds to antithrombin and enhances its ability to inhibit two of the body?s most potent clotting factors ? factor Xa and factor IIa ? usually within minutes. As with all forms of heparin, UFH doesn?t break down clots, but it keeps them from growing and stops new ones from forming. This allows the body the time necessary to gradually dissolve existing blood clots.Unfractionated Heparin Market can be devided by source (Porcine and Bovine), by Injection type (IV Injection and Subcutaneous Injection), and by disease indication (Venous Thromboembolism, Cardioversion of Atrial Fibrillation, and Pulmonary Embolism & Arterial Embolism).

Unfractionated Heparin Market contains market size and forecasts of Unfractionated Heparin in global, including the following market information:

Global Unfractionated Heparin Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Unfractionated Heparin Market Sales, 2017-2022, 2023-2028, (MT)

Global top five Unfractionated Heparin companies in 2021 (%)

The global Unfractionated Heparin market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Porcine Unfractionated Heparin Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Unfractionated Heparin include Baxter International Inc., B. Braun Melsungen AG, Fresenius SE Co. KGaA, LEO Pharma A/S, Sagent Pharmaceuticals and Pfizer Inc, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Unfractionated Heparin manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Unfractionated Heparin Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (MT)

Global Unfractionated Heparin Market Segment Percentages, by Type, 2021 (%)

Porcine Unfractionated Heparin

Bovine Unfractionated Heparin

Global Unfractionated Heparin Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (MT)

Global Unfractionated Heparin Market Segment Percentages, by Application, 2021 (%)

Hospitals

Clinics

Others

Global Unfractionated Heparin Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (MT)

Global Unfractionated Heparin Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Unfractionated Heparin revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Unfractionated Heparin revenues share in global market, 2021 (%)

Key companies Unfractionated Heparin sales in global market, 2017-2022 (Estimated), (MT)

Key companies Unfractionated Heparin sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Baxter International Inc.

B. Braun Melsungen AG

Fresenius SE Co. KGaA

LEO Pharma A/S

Sagent Pharmaceuticals

Pfizer Inc